Artículos de revistas
CXCL12 rs1801157 polymorphism and expression in peripheral blood from breast cancer patients
Fecha
2011Registro en:
CYTOKINE, v.55, n.2, p.260-265, 2011
1043-4666
10.1016/j.cyto.2011.04.017
Autor
OLIVEIRA, Karen Brajao de
GUEMBAROVSKI, Roberta Losi
ODA, Julie Massayo Maeda
MANTOVANI, Mario Sergio
CARRERA, Clisia Mara
REICHE, Edna Maria Vissoci
VOLTARELLI, Julio Cesar
HERRERA, Ana Cristina da Silva do Amaral
WATANABE, Maria Angelica Ehara
Institución
Resumen
The role of chemokines has been extensively analyzed both in cancer risk and tumor progression. Among different cytokines, CXCR4 and its ligand CXCL12 have been recently subjected to a closer examination. The single-nucleotide polymorphism (SNP) rs1801157 (previously known as CXCL12-A/SDF1-3`A) in the CXCL12 gene and the relative expression of mRNA CXCL12 in peripheral blood were assessed in breast cancer patients, since the chemokine CXCL12 and its receptor CXCR4 regulate leukocyte trafficking and many essential biological processes, including tumor growth, angiogenesis and metastasis of different types of tumors. Genotyping was performed by PCR-RFLP (polymerase chain reaction followed by restriction fragment length polymorphism) using MspI restriction enzyme and the expression analyses by quantitative RT-PCR. No difference in GG genotype and allele A carrier frequencies were observed between breast cancer patients and healthy blood donors and nor when CXCL12 mRNA expression was assessed among patients with different tumor stages. However a significant difference was observed when CXCL12 mRNA relative expression was analyzed in breast cancer patients in accordance to the presence or absence of the CXCL12 rs1801157 allele A. Allele A breast cancer patients presented a mRNA CXCL12 expression about 2.1-fold smaller than GG breast cancer patients. Estrogen positive patients presenting CXCL12 allele A presented a significantly lower expression of CXCL12 in peripheral blood (p = 0.039) than GG hormone positive patients. Our findings demonstrated that allele A is associated with low expression of CXCL12 in the peripheral blood from ER-positive breast cancer patients, which suggests implications on breast cancer clinical outcome. (C) 2011 Elsevier Ltd. All rights reserved.